| __timestamp | Blueprint Medicines Corporation | MannKind Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 79383000 |
| Thursday, January 1, 2015 | 14456000 | 108402000 |
| Friday, January 1, 2016 | 19218000 | 46928000 |
| Sunday, January 1, 2017 | 27986000 | 74959000 |
| Monday, January 1, 2018 | 47928000 | 79716000 |
| Tuesday, January 1, 2019 | 96388000 | 74669000 |
| Wednesday, January 1, 2020 | 157743000 | 59040000 |
| Friday, January 1, 2021 | 195293000 | 77417000 |
| Saturday, January 1, 2022 | 237374000 | 91473000 |
| Sunday, January 1, 2023 | 295141000 | 94314000 |
| Monday, January 1, 2024 | 359272000 |
Data in motion
In the competitive landscape of biotechnology, understanding the financial strategies of companies is crucial. Blueprint Medicines Corporation and MannKind Corporation, two prominent players, have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. Blueprint Medicines has seen a staggering increase of over 3,600% in SG&A expenses, starting from a modest $7.89 million in 2014 to nearly $295 million in 2023. This growth reflects their aggressive expansion and investment in administrative capabilities. In contrast, MannKind Corporation's SG&A expenses have remained relatively stable, with a slight increase of about 19% over the same period, peaking at approximately $108 million in 2015. This stability suggests a more conservative financial approach. These trends highlight the diverse strategies within the biotech sector, offering insights into how companies allocate resources to drive growth and maintain competitiveness.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
SG&A Efficiency Analysis: Comparing Pfizer Inc. and MannKind Corporation
Comparing SG&A Expenses: Zoetis Inc. vs MannKind Corporation Trends and Insights
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and MannKind Corporation
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ACADIA Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Celldex Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or MannKind Corporation
SG&A Efficiency Analysis: Comparing Axsome Therapeutics, Inc. and MannKind Corporation
Cost Management Insights: SG&A Expenses for CymaBay Therapeutics, Inc. and MannKind Corporation
Who Optimizes SG&A Costs Better? ACADIA Pharmaceuticals Inc. or MannKind Corporation